
Neurodegenerative Diseases Therapeutics
Description
Global Neurodegenerative Diseases Therapeutics Market to Reach US$71.7 Billion by 2030
The global market for Neurodegenerative Diseases Therapeutics estimated at US$50.4 Billion in the year 2024, is expected to reach US$71.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Immunomodulators, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Dopamine Agonists segment is estimated at 5.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$13.6 Billion While China is Forecast to Grow at 9.8% CAGR
The Neurodegenerative Diseases Therapeutics market in the U.S. is estimated at US$13.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$15.4 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
Global Neurodegenerative Diseases Therapeutics Market - Key Drivers and Trends Summarized
Neurodegenerative diseases therapeutics encompass a broad array of treatments aimed at managing and potentially altering the course of diseases characterized by progressive nervous system dysfunction. These diseases include Alzheimer`s, Parkinson`s, Huntington`s, and amyotrophic lateral sclerosis (ALS), among others. The primary focus of these therapeutics is to alleviate symptoms, improve quality of life, and, in some cases, slow disease progression. Treatments range from pharmacological interventions, such as cholinesterase inhibitors and dopamine agonists, to advanced approaches like gene therapy and neuroprotective agents.
Over the past decade, the field of neurodegenerative disease therapeutics has witnessed remarkable advancements, propelled by a deeper understanding of disease mechanisms and technological innovations. Traditional pharmacological treatments have been supplemented by novel approaches targeting the underlying pathology of these diseases. For instance, monoclonal antibodies designed to clear amyloid-beta plaques have shown promise in Alzheimer`s disease, while gene therapies are being explored for their potential to correct genetic mutations in conditions like Huntington`s disease. Additionally, the use of biomarkers for early diagnosis and personalized medicine approaches are becoming increasingly prevalent, allowing for more tailored and effective treatment strategies. Clinical trials and research efforts continue to expand, providing a pipeline of potential new therapies that could transform the management of neurodegenerative diseases.
The growth in the neurodegenerative diseases therapeutics market is driven by several factors, including technological advancements, increasing prevalence of neurodegenerative disorders, and heightened investment in research and development. Innovations in biotechnology and molecular biology have paved the way for cutting-edge treatments such as CRISPR-based gene editing and stem cell therapies, which hold the promise of addressing the root causes of these diseases. The aging global population is contributing to a higher incidence of neurodegenerative conditions, thereby increasing the demand for effective treatments. Furthermore, substantial investments from pharmaceutical companies and government agencies are fueling the development of new therapeutics. Collaborative efforts between academia, industry, and regulatory bodies are accelerating the pace of discovery and approval of new treatments. These factors, combined with a growing understanding of disease mechanisms and the advent of precision medicine, are driving the robust expansion of the neurodegenerative diseases therapeutics market, offering hope for improved outcomes for patients worldwide.
SCOPE OF STUDY:The report analyzes the Neurodegenerative Diseases Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors, Other Drug Classes); Disease Type (Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease, Other Disease Types); Distribution Channel (Drug Store & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 45 Featured) -
- AbbVie, Inc.
- Alector, Inc.
- AstraZeneca PLC
- Biohaven, Ltd.
- Bristol-Myers Squibb Company
- Coya Therapeutics
- Denali Therapeutics, Inc.
- Eli Lilly and Company
- Genentech, Inc.
- H. Lundbeck A/S
- Ionis Pharmaceuticals, Inc.
- Les Laboratoires Servier
- MD Biosciences, Inc.
- Ono Pharmaceutical Co., Ltd.
- Prothena Corporation PLC
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Global Economic Update
- Neurodegenerative Diseases Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Neurodegenerative Diseases Drives Demand for Therapeutics
- Advancements in Biomarker Research Propel Growth in Neurodegenerative Therapeutics Market
- Growing Awareness of Alzheimer's and Parkinson's Diseases Spurs Market Demand
- Innovations in Gene Therapy Generate Market Interest and Drive Adoption
- Expansion of Biopharmaceutical Sector Enhances Development of Novel Treatments
- Rising Prevalence of Comorbid Conditions Sustains Demand for Comprehensive Treatment Approaches
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Neurodegenerative Diseases Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Decarboxylase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Multiple Sclerosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Multiple Sclerosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Multiple Sclerosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Alzheimer`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Alzheimer`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Alzheimer`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Parkinson`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Parkinson`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Parkinson`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- CANADA
- TABLE 50: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 53: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- JAPAN
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 59: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 62: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- CHINA
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 68: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 71: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: China Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: China 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- EUROPE
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 77: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- FRANCE
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 89: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 92: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: France Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: France 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- GERMANY
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 98: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 101: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- ITALY
- TABLE 107: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 110: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 116: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 119: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: UK 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 125: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Spain 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 128: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Spain 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 134: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Russia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 137: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Russia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Rest of Europe 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 153: Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- AUSTRALIA
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 164: Australia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Australia Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Australia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 167: Australia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Australia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- INDIA
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 173: India Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: India Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: India 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 176: India Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: India Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: India 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 182: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: South Korea Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: South Korea 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: South Korea 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 200: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 201: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 212: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Argentina 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Argentina 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 221: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Brazil 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Brazil 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 230: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Mexico 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Mexico 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Latin America 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 248: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 249: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- IRAN
- TABLE 260: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Iran 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 263: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: Iran 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 269: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: Israel 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 272: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: Israel 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: Saudi Arabia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: Saudi Arabia 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 287: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: UAE 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 290: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: UAE 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Middle East 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- AFRICA
- Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 305: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 306: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 307: Africa 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 308: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 313: Africa 15-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer`s Disease, Parkinson`s Disease and Other Disease Types for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates